Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs
- PMID: 17239100
- DOI: 10.1111/j.1528-1167.2006.00871.x
Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs
Abstract
The availability of generic products of antiepileptic drugs (AEDs) has been increasing in recent years. In view of the importance of the issue, the Italian League against Epilepsy (LICE) set up an ad hoc working group whose task was to assess available evidence on the efficacy and safety of generic AEDs in the treatment of epilepsy and to produce recommendations on their use. A careful review of the literature revealed no adequately powered randomized controlled trials that assessed the risk/benefit ratio of generic substitution. Although there have been reports of loss or worsened seizure control, or appearance of adverse events, following the switch from brand products to generics, a critical assessment of the evidence generally does not allow us to establish a cause-effect relationship between the switch and a change in clinical status. Overall, the working group concluded that generic AEDs meeting current regulatory criteria for bioequivalence represent a valuable choice in the management of epilepsy by allowing a substantial reduction of treatment costs, particularly in patients initiating monotherapy or adjunctive treatment and in those with persistent seizures. The working group considered that in patients who achieved seizure freedom a modest change in plasma drug levels, which may occasionally occur even after substitution of products that meet bioequivalence criteria, could in rare cases lead to seizure breakthrough. Therefore, generic substitution is not recommended in patients who achieved seizure remission. Switches between a particular generic and another generic should also be preferably avoided. Finally, sustained-release AED formulations should not be used interchangeably with immediate-release brand or generic products. Patients need to be informed about the stringent criteria that currently govern the approval of generic products and about the implications of the use of generic AEDs, and their opinion should be taken into consideration at the time of prescribing.
Similar articles
-
Generic products of antiepileptic drugs (AEDs): is it an issue?Epilepsia. 2007 Oct;48(10):1825-32. doi: 10.1111/j.1528-1167.2007.01272.x. Epub 2007 Sep 10. Epilepsia. 2007. PMID: 17850324
-
Generic substitution in the treatment of epilepsy: patient and physician perceptions.Epilepsy Behav. 2008 Nov;13(4):693-9. doi: 10.1016/j.yebeh.2008.06.001. Epub 2008 Sep 10. Epilepsy Behav. 2008. PMID: 18589000
-
Current approaches to the use of generic antiepileptic drugs.Epilepsy Behav. 2007 Aug;11(1):46-52. doi: 10.1016/j.yebeh.2007.03.014. Epub 2007 May 29. Epilepsy Behav. 2007. PMID: 17537678 Review.
-
The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. doi: 10.1517/14656560903140525. Expert Opin Pharmacother. 2009. PMID: 19663636 Review.
-
Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.Epilepsia. 2010 Jun;51(6):941-50. doi: 10.1111/j.1528-1167.2010.02573.x. Epub 2010 Apr 8. Epilepsia. 2010. PMID: 20384761 Review.
Cited by
-
Evaluating Therapeutic Equivalence of Generic and Original Levetiracetam in Patients with Epilepsy: A Retrospective Study.Neurol Int. 2022 Mar 15;14(1):271-283. doi: 10.3390/neurolint14010022. Neurol Int. 2022. PMID: 35324578 Free PMC article.
-
Efficacy and safety of switching from brand-name to domestic generic levetiracetam in children with epilepsy.Zhongguo Dang Dai Er Ke Za Zhi. 2022 Mar 15;24(3):285-289. doi: 10.7499/j.issn.1008-8830.2111033. Zhongguo Dang Dai Er Ke Za Zhi. 2022. PMID: 35351259 Free PMC article. Chinese, English.
-
Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.Drugs. 2010 Mar 26;70(5):605-21. doi: 10.2165/10898530-000000000-00000. Drugs. 2010. PMID: 20329806 Free PMC article.
-
[Change from original preparations to generics. A case example with oxcarbazepine].Nervenarzt. 2010 Dec;81(12):1498-500. doi: 10.1007/s00115-010-3033-5. Nervenarzt. 2010. PMID: 20509018 German. No abstract available.
-
Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.Clin Drug Investig. 2016 Jan;36(1):87-91. doi: 10.1007/s40261-015-0351-1. Clin Drug Investig. 2016. PMID: 26507620
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical